{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:32:43Z","timestamp":1794270763277,"version":"4.9.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":70,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82473254"],"award-info":[{"award-number":["82473254"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shandong Provincial Traditional Chinese Medicine Science and Technology Project","award":["2020M015"],"award-info":[{"award-number":["2020M015"]}]},{"name":"Shandong University of Traditional Chinese Medicine Scientific Research Fund","award":["KYZK2024M05"],"award-info":[{"award-number":["KYZK2024M05"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-54690-y","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T08:03:54Z","timestamp":1779696234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimal treatment strategies for EGFR mutant advanced lung adenocarcinoma patients with targeted therapy resistance and correlation analysis of PD-L1 expression with ICI efficacy"],"prefix":"10.1038","volume":"16","author":[{"given":"Jiling","family":"Niu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoran","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuquan","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaidong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"issue":"3","key":"54690_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3), 229\u2013263 (2024).","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"54690_CR2","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","volume":"20","author":"A Leiter","year":"2023","unstructured":"Leiter, A., Veluswamy, R. R. & Wisnivesky, J. P. The global burden of lung cancer: Current status and future trends. Nat Rev Clin Oncol 20(9), 624\u2013639 (2023).","journal-title":"Nat Rev Clin Oncol"},{"issue":"48","key":"54690_CR3","doi-asserted-by":"publisher","first-page":"78985","DOI":"10.18632\/oncotarget.12587","volume":"7","author":"YL Zhang","year":"2016","unstructured":"Zhang, Y. L. et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis. Oncotarget 7(48), 78985\u201378993 (2016).","journal-title":"Oncotarget"},{"key":"54690_CR4","first-page":"1","volume":"5","author":"LY Gou","year":"2014","unstructured":"Gou, L. Y. & Wu, Y. L. Prevalence of driver mutations in non-small-cell lung cancers in the People\u2019s Republic of China. Lung Cancer (Auckl) 5, 1\u20139 (2014).","journal-title":"Lung Cancer (Auckl)"},{"issue":"2","key":"54690_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","volume":"9","author":"Y Shi","year":"2014","unstructured":"Shi, Y. et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 9(2), 154\u2013162 (2014).","journal-title":"J Thorac Oncol"},{"issue":"33","key":"54690_CR6","doi-asserted-by":"publisher","first-page":"34300","DOI":"10.18632\/oncotarget.5549","volume":"6","author":"R Wang","year":"2015","unstructured":"Wang, R. et al. Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients. Oncotarget 6(33), 34300\u201334308 (2015).","journal-title":"Oncotarget"},{"issue":"1","key":"54690_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/bjc.2013.721","volume":"110","author":"JY Douillard","year":"2014","unstructured":"Douillard, J. Y. et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: A Phase-IV, open-label, single-arm study. Br J Cancer 110(1), 55\u201362 (2014).","journal-title":"Br J Cancer"},{"issue":"10","key":"54690_CR8","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S2213-2600(23)00183-2","volume":"11","author":"S Lu","year":"2023","unstructured":"Lu, S. et al. Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study. Lancet Respir Med 11(10), 905\u2013915 (2023).","journal-title":"Lancet Respir Med"},{"issue":"2","key":"54690_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria, J. C. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378(2), 113\u2013125 (2018).","journal-title":"N Engl J Med"},{"issue":"27","key":"54690_CR10","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1200\/JCO.21.02641","volume":"40","author":"S Lu","year":"2022","unstructured":"Lu, S. et al. AENEAS: A randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR Exon 19 deletion or L858R mutations. J Clin Oncol 40(27), 3162\u20133171 (2022).","journal-title":"J Clin Oncol"},{"issue":"11","key":"54690_CR11","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","volume":"10","author":"Y Shi","year":"2022","unstructured":"Shi, Y. et al. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): A multicentre, double-blind, randomised phase 3 study. Lancet Respir. Med. 10(11), 1019\u20131028 (2022).","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"54690_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11523-021-00794-6","volume":"16","author":"Y Cheng","year":"2021","unstructured":"Cheng, Y. et al. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study. Target Oncol 16(2), 165\u2013176 (2021).","journal-title":"Target Oncol"},{"issue":"8","key":"54690_CR13","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/S1470-2045(15)00121-7","volume":"16","author":"JC Soria","year":"2015","unstructured":"Soria, J. C. et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): A phase 3 randomised trial. Lancet Oncol 16(8), 990\u2013998 (2015).","journal-title":"Lancet Oncol"},{"issue":"36","key":"54690_CR14","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1200\/JCO.2017.73.9250","volume":"35","author":"TSK Mok","year":"2017","unstructured":"Mok, T. S. K. et al. Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): Overall survival and biomarker analyses. J. Clin. Oncol. 35(36), 4027\u20134034 (2017).","journal-title":"J. Clin. Oncol."},{"issue":"34","key":"54690_CR15","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1200\/JCO.23.02747","volume":"42","author":"JC Yang","year":"2024","unstructured":"Yang, J. C. et al. Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor-resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer. J. Clin. Oncol. 42(34), 4029\u20134039 (2024).","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"54690_CR16","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.21037\/jtd.2017.07.107","volume":"9","author":"T Ding","year":"2017","unstructured":"Ding, T. et al. Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations. J. Thorac. Dis. 9(9), 2923\u20132934 (2017).","journal-title":"J. Thorac. Dis."},{"issue":"17","key":"54690_CR17","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373(17), 1627\u20131639 (2015).","journal-title":"N. Engl. J. Med."},{"issue":"10066","key":"54690_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer, A. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066), 255\u2013265 (2017).","journal-title":"Lancet"},{"issue":"4","key":"54690_CR19","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.annonc.2020.01.013","volume":"31","author":"GR Oxnard","year":"2020","unstructured":"Oxnard, G. R. et al. TATTON: A multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in mutant lung cancer. Ann. Oncol. 31(4), 507\u2013516 (2020).","journal-title":"Ann. Oncol."},{"issue":"5","key":"54690_CR20","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jtho.2019.02.001","volume":"14","author":"JCH Yang","year":"2019","unstructured":"Yang, J. C. H. et al. Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M-positive NSCLC following previous EGFR TKI therapy: CAURAL brief report. J. Thorac. Oncol. 14(5), 933\u2013939 (2019).","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"54690_CR21","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1200\/JCO.23.01017","volume":"42","author":"T Mok","year":"2024","unstructured":"Mok, T. et al. Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: Final results of CheckMate 722. J. Clin. Oncol. 42(11), 1252\u20131264 (2024).","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"54690_CR22","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S1470-2045(22)00382-5","volume":"23","author":"S Lu","year":"2022","unstructured":"Lu, S. et al. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): First interim results from a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 23(9), 1167\u20131179 (2022).","journal-title":"Lancet Oncol"},{"issue":"7","key":"54690_CR23","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/S2213-2600(23)00135-2","volume":"11","author":"S Lu","year":"2023","unstructured":"Lu, S. et al. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): Second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir. Med. 11(7), 624\u2013636 (2023).","journal-title":"Lancet Respir. Med."},{"issue":"11","key":"54690_CR24","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1200\/JCO.23.01891","volume":"42","author":"S Park","year":"2024","unstructured":"Park, S. et al. Phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung cancer (ATTLAS, KCSG-LU19-04). J. Clin. Oncol. 42(11), 1241\u20131251 (2024).","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"54690_CR25","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-08-2904","volume":"15","author":"GN Naumov","year":"2009","unstructured":"Naumov, G. N. et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin. Cancer Res. 15(10), 3484\u20133494 (2009).","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"54690_CR26","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jtho.2020.11.022","volume":"16","author":"MB Nilsson","year":"2021","unstructured":"Nilsson, M. B. et al. Altered regulation of HIF-1alpha in naive- and drug-resistant EGFR-mutant NSCLC: Implications for a vascular endothelial growth factor-dependent phenotype. J. Thorac. Oncol. 16(3), 439\u2013451 (2021).","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"54690_CR27","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S1470-2045(24)00379-6","volume":"25","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. et al. Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis. Lancet Oncol 25(10), 1347\u20131356 (2024).","journal-title":"Lancet Oncol"},{"key":"54690_CR28","doi-asserted-by":"publisher","first-page":"1512468","DOI":"10.3389\/fimmu.2024.1512468","volume":"15","author":"L Zhu","year":"2024","unstructured":"Zhu, L. et al. Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis. Front Immunol. 15, 1512468 (2024).","journal-title":"Front Immunol."},{"issue":"7","key":"54690_CR29","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jama.2024.10613","volume":"332","author":"HA-AS Investigators","year":"2024","unstructured":"Investigators, H.A.-A.S. et al. Ivonescimab plus chemotherapy in non-small cell lung cancer With EGFR variant: A randomized clinical trial. JAMA 332(7), 561\u2013570 (2024).","journal-title":"JAMA"},{"issue":"1","key":"54690_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","volume":"35","author":"A Passaro","year":"2024","unstructured":"Passaro, A. et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: Primary results from the phase III MARIPOSA-2 study. Ann. Oncol. 35(1), 77\u201390 (2024).","journal-title":"Ann. Oncol."},{"key":"54690_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7694202","volume":"2017","author":"K Suda","year":"2017","unstructured":"Suda, K. et al. Increased EGFR phosphorylation correlates with higher programmed death ligand-1 expression: Analysis of TKI-resistant lung cancer cell lines. BioMed. Res. Int. 2017, 7694202 (2017).","journal-title":"BioMed. Res. Int."},{"issue":"1","key":"54690_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1073-4","volume":"18","author":"S Peng","year":"2019","unstructured":"Peng, S. et al. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. Mol. Cancer. 18(1), 165 (2019).","journal-title":"Mol. Cancer."},{"issue":"8","key":"54690_CR33","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1158\/1078-0432.CCR-19-2027","volume":"26","author":"K Isomoto","year":"2020","unstructured":"Isomoto, K. et al. Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation-positive non-small cell lung cancer. Clin. Cancer. Res. 26(8), 2037\u20132046 (2020).","journal-title":"Clin. Cancer. Res."},{"issue":"3","key":"54690_CR34","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1158\/1078-0432.CCR-18-1102","volume":"25","author":"M Offin","year":"2019","unstructured":"Offin, M. et al. Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers. Clin. Cancer. Res. 25(3), 1063\u20131069 (2019).","journal-title":"Clin. Cancer. Res."},{"issue":"11","key":"54690_CR35","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1158\/2326-6066.CIR-16-0197","volume":"4","author":"L Galluzzi","year":"2016","unstructured":"Galluzzi, L., Zitvogel, L. & Kroemer, G. Immunological mechanisms underneath the efficacy of cancer therapy. Cancer. Immunol. Res. 4(11), 895\u2013902 (2016).","journal-title":"Cancer. Immunol. Res."},{"issue":"5","key":"54690_CR36","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","volume":"15","author":"KA Khan","year":"2018","unstructured":"Khan, K. A. & Kerbel, R. S. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat. Rev. Clin. Oncol. 15(5), 310\u2013324 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"54690_CR37","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura, D. et al. Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges. Nat. Rev. Clin. Oncol. 15(5), 325\u2013340 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"54690_CR38","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jtho.2021.09.014","volume":"17","author":"N Nogami","year":"2022","unstructured":"Nogami, N. et al. IMpower150 final exploratory analyses for Atezolizumab plus Bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain. J. Thorac. Oncol. 17(2), 309\u2013323 (2022).","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"54690_CR39","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.21037\/tlcr-21-681","volume":"10","author":"X Yu","year":"2021","unstructured":"Yu, X. et al. Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy. Transl. Lung. Cancer. Res. 10(9), 3782\u20133792 (2021).","journal-title":"Transl. Lung. Cancer. Res."},{"key":"54690_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108447","volume":"201","author":"K Morimoto","year":"2025","unstructured":"Morimoto, K. et al. Exploration of clinical biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-mutant NSCLC patients after EGFR-TKI therapy: The SPIRAL-STEP study. Lung Cancer 201, 108447 (2025).","journal-title":"Lung Cancer"},{"issue":"1","key":"54690_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70149","volume":"15","author":"SG Wu","year":"2025","unstructured":"Wu, S. G. et al. Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis. Clin. Transl. Med. 15(1), e70149 (2025).","journal-title":"Clin. Transl. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54690-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54690-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54690-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T09:55:33Z","timestamp":1785750933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54690-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["54690"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-54690-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"15 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethical Review Committee of the Affiliated Cancer Hospital of Shandong First Medical University and was conducted in accordance with the Declaration of Helsinki (Ethical approval number: SDTHEC202504008). Informed consent was obtained from all patients or their legal guardians.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"23822"}}